CO-WESTERN-UNION
14.2.2020 06:32:04 CET | Business Wire | Press release
Today, Western Union (NYSE: WU) a leader in cross-border, cross-currency money movement and payments, and the Western Union Foundation announced a USD $1M global matching challenge to help fight COVID-19 (coronavirus) and for relief in China and other affected countries. The combined Western Union and Western Union Foundation match will be up to USD $500,000.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005982/en/
The Western Union Foundation is accepting contributions from Western Union employees, Agents, customers, and the public, across the globe between now and April 14, 2020. The aid will be pledged to local and global NGOs, including Give2Asia and International Medical Corps* for ongoing relief efforts in China and other impacted nations throughout the world, including to purchase supplies, equipment and frontline medical treatment.
As of February 13, 46,997 individuals are estimated to have been infected with COVID-19, with 1,368 deaths globally (46,550 cases and 1,368 deaths in China), according to the World Health Organization .
“Western Union is a global company and we support our customers, employees and communities in times of need. The time is now for the global community to come together in support of communities affected by COVID-19,” said Western Union CEO Hikmet Ersek. “Being a responsible global company means not just serving and benefiting from an interconnected world but taking steps to care for vulnerable communities in dire times. We encourage everyone across the world including our employees, Agents and customers and partners, to step up and show their support.”
Donations towards the $1M challenge can be made via:
- Public donation appeal via the Western Union Foundation Donation Platform
- In the U.S., donations made through the Western Union mobile app between March 1 – April 14
- Company donations can be coordinated via wufoundation@wu.com
In addition to offering money for on-the-ground efforts to prevent and combat the spread of COVID-19, Western Union and the Western Union Foundation have launched a worldwide campaign to drive awareness and encourage donations from the public including Western Union employees, Agents, and customers.
“We are committed to helping our partner organizations fight this virus in whatever ways are most appropriate in their localities,” said Elizabeth Roscoe, Western Union Foundation Executive Director and Western Union Head of Corporate Brand & Purpose. “We understand the importance of doing our small part to bring the global community together to combat this infectious disease which can endanger everyone equally, without regard for boundaries of geography, ethnicity or social class.”
Give2Asia said it is thankful for the help and support from the global community, but more is always welcome. “We are grateful to everyone who is taking action in this time of need,” said Birger Stamperdahl, Give2Asia’s President and CEO. "Frontline health workers are risking their lives to help control the spread of the virus. Give2Asia sees a strong commitment on the part of the global community to support their work and to help families and communities hurt by the outbreak.”
WU-G
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of December 31, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 70 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .
About the Western Union Foundation
The Western Union Foundation believes that education is the surest pathway to economic opportunity. After nearly 20 years of impact, we are continuing to deliver against our mission with our Opportunity Beyond Borders commitment, to invest $15 million by 2022, with a focus on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. We also provide funding to communities in crisis through disaster relief and other humanitarian efforts, a key reason for forced migration. To date, more than $124 million has been given to fund projects and scholarships in 174 countries across the globe. The Western Union Foundation is a separate charitable corporation that is tax-exempt under 501(c)(3) of the US Internal Revenue Code, and receives support from The Western Union Company, its employees, Agents and business partners. Contributions to the Foundation are tax-deductible for US income tax purposes. To learn more, visit wu.com/foundation or follow us on Twitter @TheWUFoundation.
*The Western Union Foundation will commit 100 percent of funds raised via public donations to Give2Asia and International Medical Corps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
